Pharmaceuticals Global On demand · 24-48h

Global GLP-1 Agonist Market Strategic Research Report

Global GLP-1 Agonist Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global GLP-1 Agonist Market
$23B2025
17.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Long-Acting Drug, Short-Acting Drug

By Application: Diabetes, Obesity, Nonalcoholic Fatty Liver Disease, Metabolic Disorder, Alzheimer's Disease, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh, BENEMAE

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 89 pages
Market size 2025
$23B
Billion USD
Forecast CAGR
17.2%
2025-2032
Forecast 2032
$69.9B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global GLP-1 Agonist market size is predicted to grow from US$ 23,000 million in 2025 to US$ 68,600 million in 2032; it is expected to grow at a CAGR of 17.2% from 2026 to 2032.

GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.

Global key GLP-1 Agonist players cover Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Agonist market?

What factors are driving GLP-1 Agonist market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Agonist market opportunities vary by end market size?

How does GLP-1 Agonist break out by Type, by Application?

This report presents a comprehensive overview of the global GLP-1 Agonist market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Long-Acting Drug
  • Short-Acting Drug

Segment by Application

  • Diabetes
  • Obesity
  • Nonalcoholic Fatty Liver Disease
  • Metabolic Disorder
  • Alzheimer's Disease
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global GLP-1 Agonist market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Diabetes, Obesity, Nonalcoholic Fatty Liver Disease evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global GLP-1 Agonist Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 17.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$23B
2025
Forecast
$69.9B
2032
CAGR
17.2%
2025–2032
Regions
5
global
Key companies
Novo NordiskAstraZenecaSanofiGSKEli LillyZealand Pharma A/ShansohBENEMAE
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Long-Acting DrugShort-Acting Drug
By Application
DiabetesObesityNonalcoholic Fatty Liver DiseaseMetabolic DisorderAlzheimer's DiseaseOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Long-Acting Drug
  • 3.1.3 Short-Acting Drug
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Diabetes
  • 4.1.3 Obesity
  • 4.1.4 Nonalcoholic Fatty Liver Disease
  • 4.1.5 Metabolic Disorder
  • 4.1.6 Alzheimer's Disease
  • 4.1.7 Other
  • 4.1.8 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Novo Nordisk
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 AstraZeneca
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sanofi
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 GSK
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Eli Lilly
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Zealand Pharma A/S
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 hansoh
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 BENEMAE
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global GLP-1 Agonist market?
The global GLP-1 Agonist market is estimated at US$ 23 billion in 2025 (base year) and is projected to reach US$ 68.6 billion by 2032.
What is the forecast CAGR for the GLP-1 Agonist market?
The market is expected to grow at a CAGR of 17.2% from 2026 to 2032, expanding from US$ 23 billion in 2025 to US$ 68.6 billion in 2032, roughly 3.0 times its base-year value.
What is GLP-1 Agonist?
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity.
What are the main segments of the GLP-1 Agonist market by type?
By type, the market is segmented into Long-Acting Drug and Short-Acting Drug.
Which applications drive demand in the GLP-1 Agonist market?
Key applications covered include Diabetes, Obesity, Nonalcoholic Fatty Liver Disease, Metabolic Disorder, Alzheimer's Disease and Other.
Who are the key players in the GLP-1 Agonist market?
Key players profiled include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE.
Which regions and countries are covered for GLP-1 Agonist?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the GLP-1 Agonist market?
What factors are driving GLP-1 Agonist market growth, globally and by region?
Who should buy the GLP-1 Agonist market report?
The report is intended for manufacturers and solution providers, distributors and end users in Diabetes, Obesity and Nonalcoholic Fatty Liver Disease, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the GLP-1 Agonist market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.